Aqualung Therapeutics leadership are experienced academic leaders, entrepreneurs and translational scientists with expertise in Precision Medicine, who have driven NAMPT as a druggable target and novel diagnostic in acute and chronic lung inflammatory disorders.
Joe "Skip" G.N. Garcia, MD
Founder and Chief Executive Officer
University of Arizona Endowed Merlin K. DuVal MD Professor of Medicine and an elected member of the National Academy of Medicine. Dr. Garcia is a internationally recognized physican-scientist with over 30 years of research experience in pulmonary disease. For more information, click here.
EDDIE T. CHIANG, MA
Chief operating Officer
With over 15 years of high-level academic health sciences research and administrative experience, Mr. Chiang is employee #2 of Aqualung overseeing all day-to-day aspects of the research and development operations of eNamptor™. His research training is in pulmonary vascular biology, and he has contributed to the NAMPT project as the research transitions from benchside to bedside.
STAN MIELE, BA
Chief BUSINESS STRATEGY Officer
A recognized global executive with success in sales, marketing and P&L leadership in the pharmaceutical/medical device and biotech industries, Mr. Miele was formally the Chief Commercial Officer at bioLytical Laboratories and Sucampo Pharmaceuticals Inc. He will assist with Aqualung Therapeutics global alliances and company strategies toward commercialization.
Sara M. Camp, BA
Chief Research Officer
With over 15 years experience with the Garcia research group, Ms. Camp specializes in the genomic and proteomic studies of inflammatory lung injury. She is responsible for overseeing the scientific research development of eNamptor™, a fully human anti-NAMPT monoclonal antibody for treating ventilator-induced lung injury (VILI).
THE SCIENTIFIC ADVISORY BOARD
Bill Macias, MD PhD
Robert Strieter, MD